Measuring the carbon footprint of Colchicine for Long COVID - a multicenter trial from India
インドにおける多施設共同試験 - ロングCOVIDのためのコルヒチンのカーボンフットプリント測定 (AI 翻訳)
Siaa Girotra, Shani S. Thankachen, Niveditha Devasenapathy, Madhuri Dutta, Abhinav Bassi, Vivekanand Jha
🤖 gxceed AI 要約
日本語
本論文は、インドで実施されたロングCOVID治療薬コルヒチンの多施設臨床試験のカーボンフットプリントをGHGプロトコルに基づき算定した。総排出量は12.38トンCO2eで、主な要因は試験調整員の通勤（71%）、患者検査（10%）、会議（9%）などであった。臨床試験の環境影響評価フレームワークを提供する。
English
This paper calculates the carbon footprint of a multicenter clinical trial for colchicine in Long COVID in India using the GHG Protocol. Total emissions were 12.38 tonnes CO2e, driven by staff commuting (71%), patient investigations (10%), and meetings (9%). It provides a framework for assessing clinical trial emissions.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本では医療分野の脱炭素化が進んでおらず、本論文の手法は日本の臨床試験にも適用可能。特にSSBJやTCFD関連での開示が求められる製薬企業にとって参考になる。
In the global GX context
This study demonstrates a practical carbon accounting method for clinical trials, relevant to global healthcare decarbonization efforts. It aligns with TCFD/ISSB expectations for scope 3 emissions reporting in the pharmaceutical sector.
👥 読者別の含意
🔬研究者:Provides a replicable methodology for carbon footprinting clinical trials, applicable to other settings.
🏢実務担当者:Offers insights into reducing trial-related emissions, e.g., optimizing staff commute and meeting formats.
🏛政策担当者:Supports development of guidelines for low-carbon clinical research, particularly in emerging economies.
📄 Abstract（原文）
Introduction Reducing greenhouse gas (GHG) emissions from human activities is essential to combat climate change. The healthcare sector contributes to global emissions, and clinical trials play a crucial role in informing evidence-based healthcare practices. Attempts have been made to quantify emissions resulting from clinical trials to help devise effective mitigation strategies. We report carbon emissions from a multicenter clinical trial conducted in both community and hospital settings in India. Methods We audited the carbon emissions of a multicenter, placebo-controlled trial evaluating the efficacy of colchicine for Long COVID (CTRI/2021/11/038234) using the GHG Protocol Corporate Accounting and Reporting Standard and the Corporate Value Chain Standard. A three-step methodology was followed, including identification of relevant organisational stakeholders and setting the scope of the calculation, data collection by developing relevant study tools, and calculation of emissions using applicable emission factors. Results The total emissions related to the trial were 12.38 tonnes of CO2 equivalents (CO2e) for the trial duration of three years. The top contributors to the emissions were the local commute of trial coordinators and research staff (71%, 8.73 tonnes CO2e), trial meetings (9%, 1.13 tonnes CO2e), patient investigations (10%, 1.27 tonnes CO2e) and the electricity consumption at the clinical trial unit (5%, 0.61 tonnes CO2e). Conclusion The study demonstrated the feasibility of assessing the carbon footprint of a clinical trial conducted in India and provides a framework for future assessments and recommendations that can be considered during the planning and implementation of clinical trials.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1016/j.joclim.2026.100706first seen 2026-07-13 06:14:33
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。